High dose rate endobronchial brachytherapy in the management of lung cancer: Response and toxicity evaluation in 158 patients

Özkök, Serdar; Karakoyun-Çelik, Ömür; Göksel, Tuncay; Moğulkoç, Nesrin; Yalman, Deniz; Gok, Gursel; Bölükbaşı, Yasemin

doi:10.1016/j.lungcan.2008.03.018

Cited by 39 publications

(21 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The treatment takes only a few minutes and is therefore suitable for outpatient or day case use. Most centres have used fractionated regimes, typically three fractions of 5–7.5 Gy,75 76 but the treatment is also effective as a single fraction of 15 Gy 77…”

Section: Therapeutic Procedures For Malignant Disease: Malignant Airwmentioning

confidence: 99%

“…Brachytherapy has been shown to be effective in the palliation of previously untreated inoperable lung cancer, relieving cough in 20–70% of patients, dyspnoea in 25–80% and haemoptysis in 70–90% 75 76 78 79. The relief of obstructive collapse has been reported in around 25% of patients 80.…”

Section: Therapeutic Procedures For Malignant Disease: Malignant Airwmentioning

confidence: 99%

“…Brachytherapy has been used to treat radiologically-occult early-stage lung cancer 75 84. Complete endoscopic responses have been reported in 65–90% of patients, with partial responses in the remainder and 5-year survival of around 80%.…”

Section: Therapeutic Procedures For Malignant Disease: Malignant Airwmentioning

confidence: 99%

See 2 more Smart Citations

British Thoracic Society guideline for advanced diagnostic and therapeutic flexible bronchoscopy in adults

Rand

Barber²,

Goldring³

et al. 2011

Thorax

175

180

View full text Add to dashboard Cite

Section: Therapeutic Procedures For Malignant Disease: Malignant Airwmentioning

confidence: 99%

Section: Therapeutic Procedures For Malignant Disease: Malignant Airwmentioning

confidence: 99%

See 1 more Smart Citation

British Thoracic Society guideline for advanced diagnostic and therapeutic flexible bronchoscopy in adults

Rand

Barber²,

Goldring³

et al. 2011

Thorax

175

180

View full text Add to dashboard Cite

“…Characteristics of the patients that underwent 125 I seed implantation and the outcome of the treatment. hemoptysis and broncho-esophageal fistula, were occasionally observed (15,20,21). Therefore, the adverse effects of HDR brachytherapy on the airways are more thoroughly considered.…”

Section: Discussionmentioning

confidence: 99%

Trans-bronchoscopy with implantation of 125I radioactive seeds in patients with pulmonary atelectasis induced by lung cancer

Pu²,

Zhang

et al. 2015

Oncology Letters

View full text Add to dashboard Cite

Abstract.To evaluate the role of low-dose-rate interstitial brachytherapy using trans-bronchoscope 125 I radioactive seeds implantation in patients with pulmonary atelectasis induced by lung cancer, in terms of feasibility, safety, quality of life (QOL), and survival time. Between April 2008 and June 2011, 15 patients from two medical institutions that had obstructive pulmonary atelectasis caused by inoperable lung cancer were assigned to receive 125 I implantation endoluminal brachytherapy by bronchoscopy. Subsequent to the implantation of 125 I seeds, the outcomes were measured in terms of procedure success rate, reopening of atelectasis, complications associated with the procedure, Karnofsky performance status (KPS) scores and survival time. The surgical procedure was successfully performed in all 15 patients. No procedure-associated mortality occurred and the complications were mild and considered acceptable. Irritable cough and temporary increase of hemoptysis occurred in 11 (73.3%) and 10 (66.7%) patients respectively, and were the most common complications. The pulmonary atelectasis reopening rate subsequent to the procedure was 86.7, 76.9, 80.0, 75.0 and 50.0% at 2, 6, 12, 18 and 24 months, respectively. The KPS score significantly improved following the implantation of 125 I seeds and the duration of improvement ranged between 3 and 27 months. The median and mean survival times were 15.6 and 16 months, respectively. Actuarial survival rates at 6, 12 and 24 months after the procedure were 86.7, 66.7 and 13.3%, respectively. In patients with advanced lung cancer and those presenting with obstructive pulmonary atelectasis, treatment with intraluminal implantation of 125 I seeds is a safe and effective therapy option with easy accessibility.

show abstract

“…In some cases it can be used in conjunction with external beam radiotherapy in definitive cases (28,29), and in the definitive treatment of primary tracheal carcinomas (30). More commonly, HDR brachytherapy has a well-established role in the palliation of primary and recurrent endobronchial lesions (31)(32)(33)(34).…”

Section: Bronchus/tracheamentioning

confidence: 99%

American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) Practice Guideline for the Performance of High-Dose-Rate Brachytherapy

Erickson

Demanes

Hayes³

et al. 2011

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

High dose rate endobronchial brachytherapy in the management of lung cancer: Response and toxicity evaluation in 158 patients

Cited by 39 publications

References 26 publications

British Thoracic Society guideline for advanced diagnostic and therapeutic flexible bronchoscopy in adults

British Thoracic Society guideline for advanced diagnostic and therapeutic flexible bronchoscopy in adults

Trans-bronchoscopy with implantation of 125I radioactive seeds in patients with pulmonary atelectasis induced by lung cancer

American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) Practice Guideline for the Performance of High-Dose-Rate Brachytherapy

Contact Info

Product

Resources

About